Y90放射性栓塞作为肝细胞癌合并门静脉癌栓患者肝移植降期治疗的结果
本研究纳入5个意大利移植中心2010至2023年接受TARE治疗的240例HCC合并PVTT患者,61例(25.4%)实现持续降期,37例(15.4%)最终接受肝移植;竞争风险分析显示肝移植与更低的癌症相关死亡风险相关(60个月累积发生率15.8% vs 45.2%;sHR 0.221,95%CI 0.071-0.683;P=0.0087)。
要点
- TARE可使约1/4的HCC合并PVTT患者获得肝移植降期资格。
- 降期后接受肝移植者癌症相关死亡风险显著低于未移植者。
- 移植患者5年OS和RFS均为61.6%和79.3%,56.7%移植物病理示完全肿瘤坏死。
核心结论
- 放射性栓塞可使约1/4的PVTT患者降期至符合移植标准,降期后肝移植带来显著更优的肿瘤学结局。
- TARE是HCC合并PVTT患者以移植为导向的有效治疗选择,具有独特的疗效特征。
研究设计与样本
- 多中心回顾性队列研究,纳入5个意大利移植中心2010至2023年连续接受TARE治疗的HCC合并PVTT患者240例。
- 成功降期定义为影像学持续缓解至少6个月且PVTT成分达完全或部分缓解,同时满足各中心形态学标准和AFP阈值。
主要发现
- 240例中61例(25.4%)实现持续降期,37例(15.4%)最终接受肝移植。
- 竞争风险分析中,肝移植与更低的癌症相关死亡风险相关(60个月累积发生率15.8% vs 45.2%;sHR 0.221,95%CI 0.071-0.683;P=0.0087)。
- TARE至肝移植的中位时间为17个月。
- 37例移植患者移植后3年和5年OS分别为67.2%和61.6%,RFS分别为79.3%和79.3%。
- 病理显示56.7%的移植物存在完全肿瘤坏死。
关键数值与推荐
- 成功降期需影像学持续缓解至少6个月,PVTT成分达完全或部分缓解,并满足中心特异性形态学标准和AFP阈值。
临床怎么用
- 对HCC合并PVTT患者,可考虑TARE作为降期手段以争取肝移植资格。
- 降期成功后行肝移植可显著改善癌症相关生存,需结合中心标准筛选合适患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) with tumoral portal vein thrombosis (PVTT) is considered a contraindication to liver transplantation (LT). Transarterial radioembolization (TARE) may induce sustained regression of PVTT and achieve downstaging in selected patients, potentially enabling LT. The aim of this study is to assess post-LT oncological and survival outcomes in patients with HCC and PVTT who were successfully downstaged with TARE. APPROACH AND RESULTS: Consecutive patients with HCC and PVTT treated with TARE (2010-2023) at 5 Italian transplant centers were included. Successful downstaging required a sustained radiological response for at least 6 months with a complete or partial response of the PVTT component, together with fulfillment of center-specific morphological criteria and AFP thresholds. Survival analyses were conducted for the overall cohort from TARE and the transplanted patients. Among downstaged patients, cancer-related death according to transplant status was assessed using competing-risk analysis. Among 240 patients, 61 (25.4%) achieved sustained downstaging after TARE, and 37 patients (15.4%) eventually underwent LT. In competing-risk analysis, LT was associated with a lower risk of cancer-related death (60-month cumulative incidence: 15.8% vs. 45.2%; sHR 0.221, 95% CI 0.071-0.683; p =0.0087). The median time from TARE to LT was 17 months. In the 37 transplanted patients, post-LT 3-year and 5-year OS and RFS were 67.2%/61.6% and 79.3%/79.3%, respectively. Pathology showed complete tumor necrosis in 56.7% explants. CONCLUSIONS: Radioembolization downstaged ~1 in 4 PVTT patients to transplant eligibility. After downstaging, LT conferred markedly superior oncological outcomes. TARE in PVTT associated with HCC represents a valid, transplant-oriented option with a distinct efficacy profile.
引用
- Sposito C, Berardi G, Viganò M, et al. Outcomes of Y90-radioembolization as downstaging to liver transplantation in patients with hepatocellular carcinoma and tumoral portal vein thrombosis. Hepatology. 2026. PMID: 42228945. doi:10.1097/HEP.0000000000001801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。